Celgene gains option for Triphase's epigenetic cancer therapy

Celgene Corp. (NASDAQ:CELG) has acquired another option for a cancer program ahead of its acquisition by Bristol-Myers Squibb Co. (NYSE:BMY), this time via a deal with Triphase Accelerator Corp. (Toronto, Ontario.)

On Tuesday, Celgene gained an option to acquire Triphase's preclinical molecule TRPH-395 to treat blood cancers including leukemia. The small molecule inhibitor of WD repeat domain 5 (WDR5) is due to enter the clinic within 24 months to treat mixed lineage leukemia rearrangements leukemia and lymphoma, FACIT President David O'Neill told BioCentury. Triphase is majority-owned by FACIT, which invests in the development of therapies discovered at the Ontario Institute for Cancer Research...